Table 2 Articles used for Aβ and p-tau OR analyses in the Mild Cognitive Impairment (MCI) group
MCI population A+T+ vs. A-T- | |||||||
|---|---|---|---|---|---|---|---|
Study | Centre/cohort | Population | Measurement techniques (cut-offs) | Subjects (n.) | Age (mean (SD) / median (range)) | Follow-up time (months) | |
Mean (SD) | Median (range) | ||||||
ADNI | ADNI | MCI | amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL); CSF p-tau181 (>23 pg/mL) | 535 | 72.5 (7.5) | 53 (38) | 42 |
Cerami, 2015 [36] | San Raffael Inst. Milan, Italy | MCI | CSF Aβ42 (<515 pg/m); CSF p-tau181 (> 52.5 pg/mL) | 19 | 69.8 (5.7) | 29 (8.5) | 29 (15-60) |
Eckerström, 2021 [38] | Goteborg MCI study | Mixeda (55.0 % MCI) | CSF Aβ42 (≤482 ng/L); CSF p-tau181 (≥52 ng/L) | 262 | 64.2 (8.6) | 34.74 (25) | n.d.b |
Grontvedt, 2020 [14] | Department of Neurology, Univ. Hosp. Trondheim, Norway | MCI | CSF Aβ42 (<630 pg/ml); CSF p-tau181 (>66 pg/mL) | 40 | 64 (53 - 79) | n.d. | 108 (72-120) |
Hansson, 2006 [52] | Malmö University Hospital, Sweden | MCI | CSF Aβ42 (<530 ng/L); CSF p-tau181 (≥60 ng/L) | 99 | 71.8 (50 - 87) | n.d. | 62.4 (48-81.6) |
Herukka, 2005 [42] | Neurologic Department at Kuopio University Hospital, Finland | MCI | CSF Aβ42 (<452 pg/mL); CSF p-tau181 (>70 pg/mL) | 39 | 70.4 (8.2) | n.d. | 36 (6-144) |
MCI population A+T- vs. A-T- | |||||||
ADNI | ADNI | MCI | amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL); CSF p-tau181 (>23 pg/mL) | 323 | 72.5 (7.5) | 53 (38) | 42 |
Cerami, 2015 [36] | San Raffael Inst. Milan, Italy | MCI | CSF Aβ42 (<515 pg/m); CSF p-tau181 (> 52.5 pg/mL) | 16 | 69.8 (5.7) | 29 (8.5) | 29 (15-60) |
Eckerström, 2021 [38] | Goteborg MCI study | Mixed a (44.4 % MCI) | CSF Aβ42 (≤482 ng/L); CSF p-tau181 (≥52 ng/L) | 198 | 62.6 (8.3) | 31.6 (19) | n.d. |
Grontvedt, 2020 [14] | Department of Neurology, Univ. Hosp. Trondheim, Norway | MCI | CSF Aβ42 (<630 pg/ml); CSF p-tau181 (>66 pg/mL) | 26 | 64 (53 - 79) | n.d. | 108 (72-120) |
Hansson, 2006 [52] | Malmö University Hospital, Sweden | MCI | CSF Aβ42 (<530 ng/L); CSF p-tau181 (≥60 ng/L) | 44 | 71.8 (50 - 87) | n.d. | 62.4 (48-81.6) |
Herukka, 2005 [42] | Neurologic Department at Kuopio University Hospital, Finland | MCI | CSF Aβ42 (<452 pg/mL); CSF p-tau181 (>70 pg/mL) | 26 | 70.4 (8.2) | n.d. | 36 (6-144) |
MCI population A-T+ vs A-T- | |||||||
ADNI | ADNI | MCI | amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL); CSF p-tau181 (>23 pg/mL) | 275 | 72.5 (7.5) | 53 (38) | 42 |
Cerami, 2015 [36] | San Raffael Inst. Milan, Italy | MCI | CSF Aβ42 (<515 pg/m); CSF p-tau181 (> 52.5 pg/mL) | 15 | 69.8 (5.7) | 29 (8.5) | 29 (15-60) |
Eckerström, 2021 [38] | Goteborg MCI study | Mixed a (46.1 % MCI) | CSF Aβ42 (≤482 ng/L); CSF p-tau181 (≥52 ng/L) | 282 | 63.0 (7.6) | 31.6 (19) | n.d. |
Grontvedt, 2020 [14] | Department of Neurology, Univ. Hosp. Trondheim, Norway | MCI | CSF Aβ42 (<630 pg/ml); CSF p-tau181 (>66 pg/mL) | 21 | 64 (53 - 79) | n.d. | 108 (72-120) |
Hansson, 2006 [52] | Malmö University Hospital, Sweden | MCI | CSF Aβ42 (<530 ng/L); CSF p-tau181 (≥60 ng/L) | 48 | 71.8 (50 - 87) | n.d. | 62.4 (48-81.6) |
Herukka, 2005 [42] | Neurologic Department at Kuopio University Hospital, Finland | MCI | CSF Aβ42 (<452 pg/mL); CSF p-tau181 (>70 pg/mL) | 37 | 70.4 (8.2) | n.d. | 36 (6-144) |